Black Hawk Acquisition（BKHA）株式概要ブラック・ホーク・アクイジション・コーポレーションは、1つまたは複数の企業や団体との合併、株式交換、資産買収、株式購入、組織再編、または同様の企業結合を実現することに重点を置く白紙委任会社である。 詳細BKHA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性0/6配当金0/6リスク分析収益が 100 万ドル未満 ( $0 )負債は営業キャッシュフローで十分にカバーされていない マイナスの株主資本 株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るBKHA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$11.85該当なし内在価値ディスカウントEst. Revenue$PastFuture03m2016201920222025202620282031Revenue US$1.0Earnings US$0AdvancedSet Fair ValueView all narrativesBlack Hawk Acquisition Corporation 競合他社Columbus AcquisitionSymbol: NasdaqGM:COLAMarket cap: US$48.7mHorizon Space Acquisition IISymbol: NasdaqGM:HSPTMarket cap: US$52.2mRibbon AcquisitionSymbol: NasdaqCM:RIBBMarket cap: US$51.0mYHN Acquisition ISymbol: NasdaqGM:YHNAMarket cap: US$46.3m価格と性能株価の高値、安値、推移の概要Black Hawk Acquisition過去の株価現在の株価US$11.8552週高値US$11.9852週安値US$10.58ベータ0.0211ヶ月の変化1.98%3ヶ月変化n/a1年変化11.79%3年間の変化n/a5年間の変化n/aIPOからの変化16.98%最新ニュースお知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.最新情報をもっと見るRecent updatesお知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.株主還元BKHAUS Capital MarketsUS 市場7D1.1%-1.1%-0.8%1Y11.8%10.3%27.1%株主還元を見る業界別リターン: BKHA過去 1 年間で9.8 % の収益を上げたUS Capital Markets業界を上回りました。リターン対市場: BKHAは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。価格変動Is BKHA's price volatile compared to industry and market?BKHA volatilityBKHA Average Weekly Movementn/aCapital Markets Industry Average Movement3.6%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: BKHAの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のBKHAのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2023n/aKent Kaufmanwww.bhspac.comブラック・ホーク・アクイジション・コーポレーションは、1つまたは複数の企業や団体との合併、株式交換、資産買収、株式購入、組織再編、または同様の企業結合を実現することに重点を置く白紙委任会社である。同社は2023年に設立され、カリフォルニア州ダンビルに拠点を置く。もっと見るBlack Hawk Acquisition Corporation 基礎のまとめBlack Hawk Acquisition の収益と売上を時価総額と比較するとどうか。BKHA 基礎統計学時価総額US$49.18m収益（TTM）US$810.98k売上高(TTM)n/a60.7xPER（株価収益率0.0xP/SレシオBKHA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BKHA 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用-US$810.98k収益US$810.98k直近の収益報告Feb 28, 2026次回決算日該当なし一株当たり利益（EPS）0.20グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-44.5%BKHA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 02:58終値2026/05/21 00:00収益2026/02/28年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Black Hawk Acquisition Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.
お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.
お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.
お知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.
お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.
お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.
